In a closely related study, Izumi et al. found that immunohistochemical AR positivity among patients treated with ADT was associated with increased time to bladder cancer recurrence, thus implicating AR as a predictive biomarker for ADT in bladder cancer [42]. The gene discussed is AR; the disease is urinary bladder carcinoma.